NuVasive reported second quarter 2014 revenue of $190.7 million as compared with $165.7 million from the previous year.

NuVasive (NASDAQ: NUVA), which develops medical devices for spine disorders, posted $145.8 million gross profit for the second quarter 2014 compared with $117 million in the same quarter last year. Operating expenses were up to $141.2 million this year, compared with $116.9 million in the second quarter of 2013. Higher operating costs resulted from an asset impairment charge of $10.7 million to develop technology for the PCM device acquired from Cervitech in 2009 along with the cost of international expansion, according to SEC filings.

With higher operating expenses, the company reported a net loss of $4.1 million, still down from the net loss of $6.5 million in the second quarter of last year.